See more : Cardlytics, Inc. (0LEC.L) Income Statement Analysis – Financial Results
Complete financial analysis of Histogen Inc. (HSTO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Histogen Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Getac Holdings Corporation (3005.TW) Income Statement Analysis – Financial Results
- Shell plc (SHEL.L) Income Statement Analysis – Financial Results
- Zhejiang Renzhi Co., Ltd. (002629.SZ) Income Statement Analysis – Financial Results
- Zentek Ltd. (ZTEK) Income Statement Analysis – Financial Results
- Oncorus, Inc. (ONCR) Income Statement Analysis – Financial Results
Histogen Inc. (HSTO)
About Histogen Inc.
Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.77M | 919.00K | 2.06M | 11.30M | 33.59M | 35.38M | 799.05K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 220.00K | 968.00K | 2.22M | 0.00 | -4.00 | -4.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.77M | 699.00K | 1.09M | 9.09M | 33.59M | 35.38M | 799.05K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 76.06% | 52.99% | 80.41% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5.02M | 8.47M | 6.22M | 4.10M | 41.37M | 43.22M | 20.29M | 16.30M | 14.91M | 6.95M |
| General & Administrative | 9.39M | 7.80M | 6.59M | 6.21M | 10.50M | 9.71M | 10.34M | 7.83M | 7.38M | 4.65M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | -91.00K | -108.30K | -105.84K | 0.00 | 0.00 | 0.00 |
| SG&A | 9.39M | 7.80M | 6.59M | 6.21M | 10.40M | 9.60M | 10.23M | 7.83M | 7.38M | 4.65M |
| Other Expenses | 0.00 | -113.00K | 105.00K | -150.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 14.41M | 16.16M | 12.81M | 10.16M | 51.77M | 52.82M | 30.52M | 24.13M | 22.29M | 11.60M |
| Cost & Expenses | 14.41M | 16.38M | 13.77M | 12.37M | 51.86M | 52.93M | 30.63M | 24.13M | 22.29M | 11.60M |
| Interest Income | 0.00 | 0.00 | 0.00 | 568.00K | 962.00K | 892.18K | 138.41K | 67.89K | 0.00 | 0.00 |
| Interest Expense | 1.00K | 10.00K | 64.00K | 0.00 | 696.00K | 662.40K | 70.00K | 70.00K | 70.00K | 462.57K |
| Depreciation & Amortization | 140.00K | 97.00K | 98.00K | 145.00K | 91.00K | 108.30K | 105.84K | 67.86K | -538.90K | 10.45K |
| EBITDA | -10.50M | -14.90M | -18.66M | -2.86M | -17.22M | -16.63M | -29.56M | -24.01M | -22.79M | -15.14M |
| EBITDA Ratio | -278.67% | -1,680.85% | -221.95% | 9.29% | -54.15% | -49.30% | -3,720.18% | 0.00% | 0.00% | 0.00% |
| Operating Income | -10.64M | -15.46M | -11.71M | 905.00K | -18.28M | -17.55M | -29.83M | -24.15M | -22.32M | -15.62M |
| Operating Income Ratio | -282.38% | -1,681.94% | -568.92% | 8.01% | -54.42% | -49.61% | -3,733.42% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.00K | 448.00K | -7.10M | -1.93M | 267.00K | 154.07K | 98.33K | -17.92K | 0.00 | -4.02M |
| Income Before Tax | -10.64M | -15.01M | -18.82M | -3.00M | -18.01M | -17.40M | -29.73M | -24.15M | -22.32M | -15.62M |
| Income Before Tax Ratio | -282.41% | -1,633.19% | -913.89% | -26.55% | -53.62% | -49.17% | -3,721.12% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -604.00K | 6.96M | 1.90M | 963.00K | 816.47K | 168.32K | 70.00K | 70.00K | 462.57K |
| Net Income | -10.62M | -14.41M | -25.77M | -4.90M | -18.01M | -17.40M | -29.73M | -24.15M | -22.32M | -15.62M |
| Net Income Ratio | -281.80% | -1,567.46% | -1,251.77% | -43.33% | -53.62% | -49.17% | -3,721.12% | 0.00% | 0.00% | 0.00% |
| EPS | -3.46 | -7.51 | -57.16 | -8.29 | -118.60 | -121.71 | -262.55 | -1.30 | -1.44 | -2.12 |
| EPS Diluted | -3.46 | -7.51 | -57.16 | -8.29 | -118.60 | -121.71 | -262.55 | -1.30 | -1.44 | -2.12 |
| Weighted Avg Shares Out | 3.21M | 1.92M | 450.92K | 590.69K | 151.85K | 142.93K | 113.25K | 18.62M | 15.48M | 7.36M |
| Weighted Avg Shares Out (Dil) | 3.21M | 1.92M | 450.92K | 590.69K | 151.85K | 142.93K | 113.25K | 18.62M | 15.48M | 7.36M |
Histogen to Present at the H.C. Wainwright Global Investment Conference
SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today announced that Steven...
CORRECTING and REPLACING Paracrine Announces Appointment of Biotech Veteran David H. Crean, Ph.D. to the Board of Directors
SAN DIEGO--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions. The updated release reads: PARACRINE ANNOUNCES APPOINTMENT OF BIOTECH VETERAN DAVID H. CREAN, PH.D. TO THE BOARD OF DIRECTORS Paracrine, Inc., a privately-held company developing...
Histogen to Report First Quarter 2022 Financial Results and Provide Business Update
SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today announced that Histogen's...
5 Top Biotech Penny Stocks Under $1 To Watch This Week
Top penny stocks to watch under $1 in April if you like Biotech stocks. The post 5 Top Biotech Penny Stocks Under $1 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Top Biotech Penny Stocks to Buy Under $1? 3 Exploding Today
Check these 3 under $1 biotech penny stocks out for your list The post Top Biotech Penny Stocks to Buy Under $1? 3 Exploding Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Histogen to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Business Update
SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function, today announced that Histogen's...
Histogen to Report Third Quarter 2021 Financial Results on November 10, 2021
SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function, today announced that Histogen's...
7 Biotech Stocks to Buy That Have Millionaire-Maker Potential
This sector is always a risky area to gamble in. If you have the stomach for it, however, these biotech stocks could see massive gains.
Best Penny Stocks To Buy Under $1 Right Now? 5 To Watch In September
Red hot penny stocks to watch and YES all are under $1 right now. The post Best Penny Stocks To Buy Under $1 Right Now?
Histogen to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
SAN DIEGO, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function, today announced that Richard...
Source: https://incomestatements.info
Category: Stock Reports